Laboratory Co. of America Holdings (NYSE:LH) Director Sells $50,025.00 in Stock

Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson sold 250 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $200.10, for a total transaction of $50,025.00. Following the completion of the sale, the director now owns 15,722 shares in the company, valued at $3,145,972.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Laboratory Co. of America Stock Up 0.5 %

NYSE:LH opened at $201.32 on Friday. The stock has a market cap of $16.97 billion, a price-to-earnings ratio of 40.51, a PEG ratio of 1.51 and a beta of 1.02. The company has a current ratio of 0.88, a quick ratio of 0.76 and a debt-to-equity ratio of 0.39. The stock has a 50-day moving average price of $210.12 and a two-hundred day moving average price of $214.70. Laboratory Co. of America Holdings has a 1 year low of $174.20 and a 1 year high of $234.09.

Laboratory Co. of America (NYSE:LH) last announced its earnings results on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, topping the consensus estimate of $3.48 by $0.20. The firm had revenue of $3.18 billion for the quarter, compared to the consensus estimate of $3.12 billion. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period last year, the company posted $3.82 EPS. As a group, equities analysts expect that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.43%. The ex-dividend date is Tuesday, May 28th. Laboratory Co. of America’s dividend payout ratio is 57.95%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LH. McClarren Financial Advisors Inc. lifted its stake in Laboratory Co. of America by 313.2% in the 1st quarter. McClarren Financial Advisors Inc. now owns 219 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 166 shares in the last quarter. Commerce Bank lifted its position in shares of Laboratory Co. of America by 6.6% in the first quarter. Commerce Bank now owns 33,934 shares of the medical research company’s stock worth $7,413,000 after purchasing an additional 2,101 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S boosted its holdings in Laboratory Co. of America by 28.7% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 2,298 shares of the medical research company’s stock worth $502,000 after purchasing an additional 513 shares during the last quarter. Financial Counselors Inc. grew its position in Laboratory Co. of America by 0.6% in the first quarter. Financial Counselors Inc. now owns 50,511 shares of the medical research company’s stock valued at $11,035,000 after purchasing an additional 315 shares in the last quarter. Finally, FORA Capital LLC acquired a new stake in Laboratory Co. of America in the 1st quarter valued at $4,149,000. 95.94% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Truist Financial cut their price target on Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, April 26th. Argus upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a research note on Monday, March 25th. TheStreet downgraded shares of Laboratory Co. of America from a “b-” rating to a “c+” rating in a research note on Thursday, February 15th. Robert W. Baird dropped their price objective on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a research note on Friday, April 26th. Finally, SVB Leerink began coverage on shares of Laboratory Co. of America in a research report on Monday, February 26th. They set an “outperform” rating and a $260.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $243.14.

Laboratory Co. of America Company Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).